A phase I clinical trial has been completed on a population of patients with PD-L1-positive gastric cancer, and pembrolizumab (a PD-1 antibody) has antitumor activity and manageable toxicity, warranting further phase II and III trials [22]. Here, CD274 is linked to gastric cancer.